---
title: Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease
date: '2023-11-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37966285/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231115170846&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Among persons with early Alzheimer''s disease, the use
  of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but
  was not associated with slower clinical decline. (Funded by F. Hoffmann-La Roche;
  GRADUATE I and II ClinicalTrials.gov numbers, NCT03444870 and NCT03443973, ...'
disable_comments: true
---
CONCLUSIONS: Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. (Funded by F. Hoffmann-La Roche; GRADUATE I and II ClinicalTrials.gov numbers, NCT03444870 and NCT03443973, ...